Summary of Purpose
To test the safety and pharmacokinetics GV150526 in patients with a clinical diagnosis of acute ischemic stroke managed in North American centers.Read More →
The following dates are available for this trial. Trial information last updated on 12 August 2008.
|Start Date||First Received||1st Completion||Completion||Verification||Results|
- Glaxo Wellcome, Research Triangle, NC
Randomized (2:1), double-blind, and placebo controlled involving 19 centers. GAIN 1 (GLYA2001; United States only) was designed as a sequential dose escalation study.